Production (Stage)
Aurinia Pharmaceuticals Inc.
AUPH
$8.08
-$0.19-2.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.47M | 59.87M | 67.77M | 57.19M | 50.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.47M | 59.87M | 67.77M | 57.19M | 50.30M |
| Cost of Revenue | 14.32M | 13.66M | 9.08M | 12.99M | 13.30M |
| Gross Profit | 48.15M | 46.21M | 58.69M | 44.20M | 37.00M |
| SG&A Expenses | 20.34M | 37.03M | 42.37M | 44.93M | 47.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.43M | 1.39M | 4.57M | -290.00K | -4.13M |
| Total Operating Expenses | 39.09M | 52.09M | 56.02M | 57.63M | 56.87M |
| Operating Income | 23.38M | 7.78M | 11.75M | -441.00K | -6.57M |
| Income Before Tax | 24.35M | 1.17M | 14.81M | 1.48M | -10.01M |
| Income Tax Expenses | 1.01M | -256.00K | 457.00K | 756.00K | 739.00K |
| Earnings from Continuing Operations | 23.34M | 1.43M | 14.35M | 722.00K | -10.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.34M | 1.43M | 14.35M | 722.00K | -10.75M |
| EBIT | 23.38M | 7.78M | 11.75M | -441.00K | -6.57M |
| EBITDA | 28.24M | 12.64M | 16.64M | 4.40M | -1.72M |
| EPS Basic | 0.17 | 0.01 | 0.10 | 0.01 | -0.07 |
| Normalized Basic EPS | 0.12 | 0.07 | 0.06 | 0.01 | -0.01 |
| EPS Diluted | 0.16 | 0.01 | 0.10 | 0.01 | -0.07 |
| Normalized Diluted EPS | 0.11 | 0.07 | 0.06 | 0.01 | -0.01 |
| Average Basic Shares Outstanding | 138.92M | 142.18M | 143.05M | 143.33M | 144.01M |
| Average Diluted Shares Outstanding | 143.20M | 147.68M | 145.65M | 144.11M | 144.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |